Oculomics explores whether retinal imaging can provide biomarkers for systemic diseases. Population studies show statistical associations between retinal features and conditions like cardiovascular disease and neurodegeneration, but clinical utility for screening or diagnosis remains investigational.
What oculomics means
Oculomics refers to the study of retinal imaging biomarkers that may correlate with systemic health conditions. The retina offers direct visualization of neural tissue and microvasculature, making it theoretically attractive for detecting systemic disease patterns.
The biological rationale
The retina shares embryological origins with the brain, contains directly visible microvasculature affected by systemic vascular disease, and may exhibit changes that parallel processes elsewhere in the body. This makes it a candidate window into systemic health.
What research has shown
Large population studies have demonstrated associations between retinal vascular features and cardiovascular disease risk. AI models have been trained to predict conditions including diabetes, kidney disease, cardiovascular events, and correlates of neurological conditions from fundus photographs. These associations are statistically significant in research datasets.
Association versus utility
Demonstrating that a retinal feature correlates with a disease is different from proving that retinal screening adds clinical value. Many oculomics associations involve conditions we already screen for directly (diabetes, hypertension). The key question is whether retinal imaging provides information beyond standard clinical assessment.
Current evidence gaps
Most oculomics studies are retrospective or cross-sectional. Prospective validation showing that retinal screening improves patient outcomes is largely absent. Sensitivity and specificity for specific conditions often fall short of clinical screening requirements. Cost-effectiveness compared to established screening methods is unclear.
Where this could matter
Oculomics may eventually contribute to integrated risk assessment, particularly if retinal imaging becomes routine for other reasons. The field could identify high-risk individuals for closer monitoring. But replacing established screening approaches would require substantial additional evidence.
Appropriate perspective
The retina does contain information about systemic health—that much is established. Whether this information is clinically actionable, adds value over existing tools, and justifies the cost and complexity of retinal screening for systemic disease remains an open research question.
Evidence should be inspectable.
This article is part of the earlier V1 library. We are progressively upgrading each piece with primary literature, structured references and explicit limitations.
Read our editorial standard →